Argenx SE (NASDAQ:ARGX) released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Seeking to build out its pipeline-in-a-product Vyvgart, Argenx is returning to its roots with plans to pursue an expanded approval in the drug’s initial myasthenia gravis indication. | On Monday, ...

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder targeting the peripheral nervous system, causing muscle weakness and sensory issues. Often considered the ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $785.09, a high estimate of $1070.00, and a low estimate of $715.00. This current ...

Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis ...

While counties are required to set aside at least 30 percent of their budgets to development projects, CoB documents also ...

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder targeting the peripheral nervous system, causing muscle weakness and sensory issues. Often considered the chronic ...

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder targeting the peripheral nervous system, causing muscle weakne ...

Remegen's Telitacicept met its primary endpoints in a Chinese trial, while a US-based Phase III trial in Sjögren's syndrome ...

Roivant Sciences Ltd.'s Vant model offers risk-isolated growth and monetization flexibility. Click for key ROIV drivers ...